CDKN1C and acute myeloid leukemia: More interestingly, EVs derived from bone marrow mesenchymal stem cells promote the development of acute myeloid leukemia (AML) through miR-221-3p, which directly targets the 3′-UTR of cyclin-dependent kinase inhibitor 1C (CDKN1C) that encodes p57KIP2, resulting in the acceleration of the cell cycle, proliferation, and invasion of AML [83].